---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-017844"
form_type: "8-K"
ticker: "ARWR"
cik: "0000879407"
company_name: "ARROWHEAD PHARMACEUTICALS, INC."
filed_at: "2025-04-15T23:59:59+00:00"
generated_at: "2026-05-23T15:15:20.144624+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Arrowhead CFO Ken Myszkowski to retire May 13; Daniel Apel named new CFO

## Summary
- Ken Myszkowski will retire as CFO effective May 13, 2025, after 16 years; no disagreement cited.
- Daniel Apel, former Global Head of FP&A at Walgreens Boots Alliance and Bayer US CFO, appointed CFO same date.
- Apel receives $575K base salary, 45% target bonus, 100K RSUs vesting over 4 years, and up to $200K relocation.
- Myszkowski will serve as adviser through Jan 31, 2026, at $200K annual salary with continued benefits and equity vesting.
- CEO cites transition to commercial stage with planned plozasiran launch pending regulatory review.

## SEC filing metadata
- accession: 0001628280-25-017844
- form_type: 8-K
- ticker: ARWR
- cik: 0000879407
- company_name: ARROWHEAD PHARMACEUTICALS, INC.
- filed_at: 2025-04-15T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/879407/000162828025017844/0001628280-25-017844-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/879407/000162828025017844/arwr-20250411.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-017844
- JSON: https://secwatch.observer/filing/0001628280-25-017844.json
- Plain text: https://secwatch.observer/filing/0001628280-25-017844.txt

## Key facts
- Executive change
  Ken Myszkowski departed as Chief Financial Officer at ARROWHEAD PHARMACEUTICALS, INC..
  - Action: retire
  - Role: Chief Financial Officer
  source text: Ken Myszkowski notified Arrowhead Pharmaceuticals, Inc. (the “Company”) of his decision to retire as Chief Financial Officer of the Company, effective as of May 13, 2025
  evidence_url: https://www.sec.gov/Archives/edgar/data/879407/000162828025017844/0001628280-25-017844-index.htm
- Executive change
  Daniel Apel was appointed as Chief Financial Officer at ARROWHEAD PHARMACEUTICALS, INC..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: the Company determined that it would appoint Daniel Apel to serve as Chief Financial Officer of the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/879407/000162828025017844/0001628280-25-017844-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.